VATOREX AG

Their core work

VATOREX AG is a Swiss agri-tech SME that develops chemical-free treatment technology for controlling Varroa destructor mite infestations in honey bee colonies — one of the most economically damaging threats to global apiculture. Their core product is a physical, eco-positive treatment system embedded in the hive that eliminates mites without synthetic pesticides or organic acids, protecting both bee health and honey purity. The company has moved from early-stage feasibility through full commercial-scale development, backed by EU SME Instrument funding. Their work sits at the intersection of precision agriculture, animal health, and sustainable food systems.

What they specialise in

How they've shifted over time

VATOREX's H2020 record spans only 2019–2023 and covers a single technology across two successive phases, so evolution here is one of scale and maturity rather than thematic shift. The Phase 1 project (2019, EUR 50,000) carried no keywords, indicating an early-stage proof-of-concept focused on validating technical and market feasibility. By Phase 2 (2020–2023, EUR 1.64M), their focus crystallised around a specific vocabulary — varroa mites, honey bees, beekeepers, chemical-free, eco-positive treatment — signalling a fully defined product identity ready for commercial rollout. The trajectory is linear: from concept validation to full-scale market entry within a four-year window.

VATOREX is on a clear commercialisation trajectory — having completed Phase 2 development, they are likely seeking distribution partnerships, regulatory approvals in additional markets, and possibly integration with precision beekeeping monitoring platforms.

How they like to work

VATOREX operates exclusively as a solo coordinator with no recorded consortium partners across either project — a pattern typical of SME Instrument grants, which are designed for single-company innovation. This means they are not experienced consortium builders and likely prefer direct bilateral relationships over complex multi-partner structures. A future collaboration would most likely take the form of a technology licensing arrangement, a joint demonstration project, or a subcontracting relationship where they provide the varroa treatment component.

VATOREX has no recorded H2020 consortium partners and has not co-participated with organisations in other countries under these grants. Their EU network is narrow by design — SME Instrument projects are intentionally single-beneficiary — but their commercial network in apiculture likely extends across European beekeeping markets.

What sets them apart

VATOREX occupies a rare niche: they are one of very few companies globally with a validated, commercially developed physical (non-chemical) varroa mite treatment backed by multi-year EU funding and field deployment. Unlike research institutes working on bee health in the abstract, VATOREX is a product company with a specific device already in the hands of beekeepers. For any consortium addressing pollinator health, sustainable agriculture, or food system resilience, they bring something that academic partners cannot: a working, market-ready technology and direct access to the beekeeping industry.

Highlights from their portfolio

• VATOREX
  The Phase 2 project (2020–2023, EUR 1.64M) is notable as one of the larger SME Instrument awards in the apiculture sector, funding the full commercial development of a chemical-free varroa treatment device from prototype to market-ready product.
• VATOREX
  The Phase 1 project (2019, EUR 50,000) demonstrates a disciplined innovation pathway — using the feasibility phase to de-risk before committing to full-scale development, a model rarely followed so cleanly by early-stage agri-tech SMEs.